Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma

Journal of Clinical Oncology

Volumn 25, Issue 30, 2007, Pages 4730-4735

  Shah, Gaurav D ^a   Yahalom, Joachim ^a   Correa, Denise D ^a   Lai, Rose K ^a   Raizer, Jeffrey J ^a   Schiff, David ^a   LaRocca, Renato ^a   Grant, Barbara ^a   DeAngelis, Lisa M ^a   Abrey, Lauren E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; FOLINIC ACID; METHOTREXATE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ARTICLE; BRAIN LYMPHOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COGNITION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG BRAIN LEVEL; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEPTIC SHOCK; STANDARD; THROMBOCYTOPENIA; TREATMENT RESPONSE; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOMA; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PROSPECTIVE STUDY; REMISSION; SKULL IRRADIATION; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; CYTARABINE; FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHOMA; MALE; METHOTREXATE; MIDDLE AGED; PROCARBAZINE; PROSPECTIVE STUDIES; REMISSION INDUCTION; TREATMENT OUTCOME; VINCRISTINE;

EID: 36048998775     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.5062     Document Type: Article

References (21)

1. DeAngelis LM, Seiferheld W, Schold SC, et al: Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 20:4643-4648, 2002
2. Shah GD, DeAngelis LM: Treatment of primary central nervous system lymphoma. Hematol Oncol Clin North Am 19:611-627, v, 2005
3. Gavrilovic IT, Hormigo A, Yahalom J, et al: Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 24:4570-4574, 2006
4. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al: IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 15:3266-3274, 1997
5. Maloney DG, Grillo-Lopez AJ, White CA, et al: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188-2195, 1997
6. Maloney DG, Liles TM, Czerwinski DK, et al: Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84:2457-2466, 1994
7. Raizer J, DeAngelis LM, Zelenetz AD, et al: Activity of Rituximab in Primary Central Nervous System Lymphoma (PCNSL). Proc Am Soc Clin Oncol 19:166a, 2000 (abstr 642)
8. Ruhstaller TW, Amsler U, Cerny T: Rituximab: Active treatment of central nervous system involvement by non-Hodgkin's lymphoma? Ann Oncol 11:374-375, 2000
9. Abrey LE, DeAngelis LM, Yahalom J: Longterm survival in primary CNS lymphoma. J Clin Oncol 16:859-863, 1998
10. Nelson DF, Martz KL, Bonner H, et al: Non-Hodgkin's lymphoma of the brain: Can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 23:9-17, 1992
11. Diehl V, Brillant C, Engert A: HD10: Investigating reduction of combined modality treatment intensity in early stage Hodgkin's lymphoma: Interim analysis of a randomized trial of the German Hodgkin Study Group (GHSG). J Clin Oncol 23:561s, 2005 (abstr 6506)
12. Hoskin P: Radiation dose in non-Hodgkin's lymphoma: Preliminary results of UK NCRN randomized trial. Ann Oncol 16:v51-v53, 2005 (suppl)
13. Loeffler M, Diehl V, Pfreundschuh M, et al: Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease. J Clin Oncol 15:2275-2287, 1997
14. Abrey LE, Batchelor TT, Ferreri AJ, et al: Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23:5034-5043, 2005
15. Moskowitz C, Hamlin PA, Horwitz SM, et al: Phase II trial of dose-dense R-CHOP followed by risk-adapted consolidation with either ICE or ICE and ASCT, based upon the results of biopsy confirmed abnormal interim restaging PET scan, improves outcome in patients with advanced stage DLBCL. Blood 108:11, 2006 (abstr 532)
16. Davidge-Pitts M, Dansey R, Bezwoda WR: Prolonged survival in follicular non Hodgkin's lymphoma is predicted by achievement of complete remission with initial treatment: Results of a longterm study with multivariate analysis of prognostic factors. Leuk Lymphoma 24:131-140, 1996
17. Armitage JO, Weisenburger DD, Hutchins M, et al: Chemotherapy for diffuse large-cell lymphoma: Rapidly responding patients have more durable remissions. J Clin Oncol 4:160-164, 1986
18. Bessell EM, Lopez-Guillermo A, Villa S, et al: Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: An analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol 20:231-236, 2002
19. Abrey LE, Ben-Porat L, Panageas KS, et al: Primary central nervous system lymphoma: The Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24:5711-5715, 2006
20. Batchelor T, Carson K, O'Neill A, et al: Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: A report of NABTT 96-07. J Clin Oncol 21:1044-1049, 2003
21. Ferreri AJ, Dell'Oro S, Foppoli M, et al: MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. Neurology 66:1435-1438, 2006